Cargando…

Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed

BACKGROUND: Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. METHODS: Clinical characteristics and outcome of localized GN/GNBI were retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Decarolis, Boris, Simon, Thorsten, Krug, Barbara, Leuschner, Ivo, Vokuhl, Christian, Kaatsch, Peter, von Schweinitz, Dietrich, Klingebiel, Thomas, Mueller, Ingo, Schweigerer, Lothar, Berthold, Frank, Hero, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964292/
https://www.ncbi.nlm.nih.gov/pubmed/27465021
http://dx.doi.org/10.1186/s12885-016-2513-9
_version_ 1782445077033910272
author Decarolis, Boris
Simon, Thorsten
Krug, Barbara
Leuschner, Ivo
Vokuhl, Christian
Kaatsch, Peter
von Schweinitz, Dietrich
Klingebiel, Thomas
Mueller, Ingo
Schweigerer, Lothar
Berthold, Frank
Hero, Barbara
author_facet Decarolis, Boris
Simon, Thorsten
Krug, Barbara
Leuschner, Ivo
Vokuhl, Christian
Kaatsch, Peter
von Schweinitz, Dietrich
Klingebiel, Thomas
Mueller, Ingo
Schweigerer, Lothar
Berthold, Frank
Hero, Barbara
author_sort Decarolis, Boris
collection PubMed
description BACKGROUND: Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. METHODS: Clinical characteristics and outcome of localized GN/GNBI were retrospectively compared to localized neuroblastoma (NB) and ganglioneuroblastoma-nodular (GNBN) registered in the German neuroblastoma trials between 2000 and 2010. RESULTS: Of 808 consecutive localized NT, 162 (20 %) were classified as GN and 55 (7 %) as GNBI. GN/GNBI patients presented more often with stage 1 disease (68 % vs. 37 %, p < 0.001), less frequently with adrenal tumors (31 % vs. 43 %, p = 0.001) and positive mIBG-uptake (34 % vs. 90 %, p < 0.001), and had less often elevated urine catecholamine metabolites (homovanillic acid 39 % vs. 62 %, p < 0.001, vanillylmandelic acid 27 % vs. 64 %, p < 0.001). Median age at diagnosis increased with grade of differentiation (NB/GNBN: 9; GNBI: 61; GN-maturing: 71; GN-mature: 125 months, p < 0.001). Complete tumor resection was achieved at diagnosis in 70 % of 162 GN and 67 % of 55 GNBI, and after 4 to 32 months of observation in 4 GN (2 %) and 5 GNBI (9 %). Eleven patients received chemotherapy without substantial effect. Fifty-five residual tumors (42 GN, 13 GNBI) are currently under observation (median: 44 months). Five patients (3 GN, 2 GNBI) showed local progression; all had tumor residuals > 2 cm. No progression occurred after subtotal resection. Two patients died of treatment, none of tumor progression. CONCLUSIONS: GN/GNBI account for one quarter of localized NT and differ from immature tumors in their clinical features. Chemotherapy is not effective. Subtotal resection appears to be a sufficient treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifiers - NB97 (NCT00017225; registered June 6, 2001); NB2004 (NCT00410631; registered December 11, 2006) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2513-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4964292
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49642922016-07-29 Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed Decarolis, Boris Simon, Thorsten Krug, Barbara Leuschner, Ivo Vokuhl, Christian Kaatsch, Peter von Schweinitz, Dietrich Klingebiel, Thomas Mueller, Ingo Schweigerer, Lothar Berthold, Frank Hero, Barbara BMC Cancer Research Article BACKGROUND: Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. METHODS: Clinical characteristics and outcome of localized GN/GNBI were retrospectively compared to localized neuroblastoma (NB) and ganglioneuroblastoma-nodular (GNBN) registered in the German neuroblastoma trials between 2000 and 2010. RESULTS: Of 808 consecutive localized NT, 162 (20 %) were classified as GN and 55 (7 %) as GNBI. GN/GNBI patients presented more often with stage 1 disease (68 % vs. 37 %, p < 0.001), less frequently with adrenal tumors (31 % vs. 43 %, p = 0.001) and positive mIBG-uptake (34 % vs. 90 %, p < 0.001), and had less often elevated urine catecholamine metabolites (homovanillic acid 39 % vs. 62 %, p < 0.001, vanillylmandelic acid 27 % vs. 64 %, p < 0.001). Median age at diagnosis increased with grade of differentiation (NB/GNBN: 9; GNBI: 61; GN-maturing: 71; GN-mature: 125 months, p < 0.001). Complete tumor resection was achieved at diagnosis in 70 % of 162 GN and 67 % of 55 GNBI, and after 4 to 32 months of observation in 4 GN (2 %) and 5 GNBI (9 %). Eleven patients received chemotherapy without substantial effect. Fifty-five residual tumors (42 GN, 13 GNBI) are currently under observation (median: 44 months). Five patients (3 GN, 2 GNBI) showed local progression; all had tumor residuals > 2 cm. No progression occurred after subtotal resection. Two patients died of treatment, none of tumor progression. CONCLUSIONS: GN/GNBI account for one quarter of localized NT and differ from immature tumors in their clinical features. Chemotherapy is not effective. Subtotal resection appears to be a sufficient treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifiers - NB97 (NCT00017225; registered June 6, 2001); NB2004 (NCT00410631; registered December 11, 2006) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2513-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-27 /pmc/articles/PMC4964292/ /pubmed/27465021 http://dx.doi.org/10.1186/s12885-016-2513-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Decarolis, Boris
Simon, Thorsten
Krug, Barbara
Leuschner, Ivo
Vokuhl, Christian
Kaatsch, Peter
von Schweinitz, Dietrich
Klingebiel, Thomas
Mueller, Ingo
Schweigerer, Lothar
Berthold, Frank
Hero, Barbara
Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
title Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
title_full Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
title_fullStr Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
title_full_unstemmed Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
title_short Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
title_sort treatment and outcome of ganglioneuroma and ganglioneuroblastoma intermixed
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964292/
https://www.ncbi.nlm.nih.gov/pubmed/27465021
http://dx.doi.org/10.1186/s12885-016-2513-9
work_keys_str_mv AT decarolisboris treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT simonthorsten treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT krugbarbara treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT leuschnerivo treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT vokuhlchristian treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT kaatschpeter treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT vonschweinitzdietrich treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT klingebielthomas treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT muelleringo treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT schweigererlothar treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT bertholdfrank treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed
AT herobarbara treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed